Table 1.
Clinical and laboratory features of case series.
| Variable |
Alive |
Deceased |
All cases |
|---|---|---|---|
| (*3 cases without outcome information) | |||
| Age-yr | |||
| Median | 45.5 (IQR 19.3) | 37 (IQR 18) | 41 (IQR 21.3) |
| Range | 23–75 | 28–86 | 23–86 |
| Total | 16 | 19 | 38*3 |
| Sex n/total (%) | |||
| Female | 12/16 (75%) | 10/20 (50%) | 24/39 (61.5%) |
| Male | 4/16 (25%) | 10/20 (50%) | 15/39 (38.5%) |
| Total | 16 | 20 | 39 |
|
Days from vaccination to symptoms*1 | |||
| Median | 9 (IQR 8) | 8 (IQR 3) | 8 (IQR 6) |
| Range | 0–37 | 0–11 | 0–37 |
| Total | 13 | 20 | 36*4 |
|
Days since onset of VITT symptoms and hospital admission | |||
| Median | 0 (IQR 5) | 4 (IQR 6) | 3 (IQR 7) |
| Range | 0–8 | 0–12 | 0–12 |
| Total | 8 | 19 | 29*5 |
|
Platelet count – per µL | |||
| Median | 46,500 (IQR 49,500) | 23,000 (IQR 35,500) | 34,000 (IQR 45,000) |
| Range | 2,000–147,000 | 8,000–113,000 | 2,000–147,000 |
| Total | 16 | 20 | 39 |
| D-dimer (FEU) | |||
| Median | 10,700 (IQR 18,560) | 41,000 (IQR 87,845) | 19,235 (IQR 33,356) |
| Range | 1,119–40,800 | 4,000–128,000 | 1,119–128,000 |
| Total | 12 | 13 | 28*6 |
| Anti-PF4 Elisa*2 | |||
| Positive | 6 | 12 | 18 |
| Negative | 8 | 1 | 12 |
| Total | 14 | 13 | 30*7 |
*1 interval between vaccine and symptoms (assuming the date of the dose applied closely to event onset).
*2 nine results were not available.
*3 one without age information.
*4 this information was not available in 3 cases.
*5 this information was not available in 10 cases.
*6 this information was not available in 11 cases.
*7 this information was not available in 09 cases.